Taysha Gene Therapies, Inc. (TSHA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8776191061
Taysha Gene Therapies, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 9.77 m USD |
| Operating income | -110.50 m USD |
| EBIT | -118.16 m USD |
| Net income | -109.00 m USD |
| Diluted EPS – continuing operations | -0.34 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
More stocks
- Duerr (DUE.DE)
- Elemental Royalty Corp (ELE.V)
- FIH Mobile Ltd (2038.HK)
- Inmyshow Digital Technology Group Co Ltd (600556.SS)
- Shoals Technologies Group, Inc. (SHLS)
- TeamViewer (TMV.DE)
- GOODYEAR TIRE & RUBBER CO /OH/ (GT)
- Precision Drilling Corporation(Calgary) (PD.TO)
- Hefei Metalforming Mach Tool (603011.SS)
- Hopson Development Holdings Ltd (754.HK)
- CLASSYS Inc (214150.KQ)
- Viel et Compagnie SA (VIL.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.